Patrick Philibert

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora et al. · New England Journal of Medicine · 2020 · 427 citations · Full text

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Chloe Orkin, Shinichi Oka, Patrick Philibert et al. · The Lancet HIV · 2021 · 166 citations

Treatment And Prevention, Medicine, Antiviral Drug Development +9

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Onyema Ogbuagu, Peter Ruane, Daniel Podzamczer et al. · The Lancet HIV · 2021 · 88 citations · Full text

Preventive Medicine, Week 96, Treatment And Prevention +10

Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure

Sofiane Mohamed, Guillaume Pénaranda, Dimitri Gonzalez et al. · AIDS · 2014 · 68 citations

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254

Christoph D. Spinner, Franco Felizarta, Giuliano Rizzardini et al. · Clinical Infectious Diseases · 2022 · 20 citations · Full text